LOGO
LOGO

Canadian News

BioNTech (BNTX) Is Up 170% In 3 Months, Busy Year Ahead

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

The American depositary shares of BioNTech SE (BNTX), which made market debut as recently as October 10, 2019, are up an impressive 170 percent based on yesterday's closing price of $44.58.

Germany-based BioNTech is a clinical-stage biotechnology company developing specific immunotherapies for the treatment of cancer and other serious diseases.

The Company has a development pipeline of over 20 product candidates, of which nine have entered into clinical trials. The clinical data updates for up to 5 oncology programs are expected by the end of 2020.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.